Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 4trametinib 3pembrolizumab 3Specimen Handling 3ulixertinib 2larotrectinib 2binimetinib 2Surveys and Questionnaires 2Radiosurgery 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cisplatin 2Biopsy 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1naporafenib 1lenvatinib 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × CALAA-01 × Dermatologic × Clear all
NCT00689065 2013-11-01

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Calando Pharmaceuticals

Phase 1 Terminated
24 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡